•
Mar 31, 2022

Sight Sciences Q1 2022 Earnings Report

Reported financial results, demonstrating revenue growth and expanded gross margin.

Key Takeaways

Sight Sciences reported a strong first quarter with a 72% increase in revenue compared to the prior year period, driven by growth in both Surgical Glaucoma and Dry Eye segments. The company also expanded its gross margin to 80%.

Total revenue increased by 72% to $14.9 million compared to the prior year period.

The number of facilities ordering the OMNIĀ® Surgical System increased from 760 to 811.

The installed base of TearCareĀ® facilities grew from 562 to 635.

Gross margin expanded to 80% compared to 73% in the prior year period.

Total Revenue
$14.9M
EPS
-$0.49
Gross Margin
80%
Operating Expenses
$34M
Gross Profit
$11.8M
Cash and Equivalents
$239M
Free Cash Flow
-$22.2M
Total Assets
$259M

Sight Sciences

Sight Sciences

Sight Sciences Revenue by Segment

Forward Guidance

Sight Sciences projects full year 2022 revenue to range from $67 million to $75 million, representing growth of approximately 37% to 53% compared to 2021.

Revenue & Expenses

Visualization of income flow from segment revenue to net income